ArticleJCI insight2020

Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes.

Cristiano P Vieira et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.